FrancophonIA/ELRC3.0 huggingface dataset:
English: <For storage conditions after <reconstitution> <dilution> <first opening> of the medicinal product, see section 6.3>
Slovenian: <Za pogoje shranjevanja po <rekonstituciji> <redčenju> <prvem odprtju> zdravila glejte poglavje 6.3.>
English: <Mechanism of action>
Slovenian: <Mehanizem delovanja>
English: <{X} is indicated in <adults> <neonates> <infants> <children> <adolescents> <aged {x to y}> <years> <months>.>
Slovenian: <Zdravilo {X} je indicirano pri <odraslih> <novorojencih> <dojenčkih> <otrocih> <mladostnikih> <starih {x do y}> <let> <mesecev>.>
English: Children <and adolescents>
Slovenian: Otroci <in mladostniki>
English: <{Name of the Member State}> <{Name of the medicinal product}>
Slovenian: <{Ime države članice}> <{Ime zdravila}>
English: <Read all of this leaflet carefully before you start <taking> <using> this medicine because it contains important information for you.
Slovenian: <Pred začetkom <jemanja> <uporabe> zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
English: Detailed information is available on the website of {name of MS/Agency}>
Slovenian: Podrobne informacije so objavljene na spletni strani {Ime države članice/Agencije}>
English: SUMMARY OF PRODUCT CHARACTERISTICS,
Slovenian: POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA,
English: <Excipient(s) with known effect>
Slovenian: <Pomožna(e) snov(i) z znanim učinkom:>
English: <Pharmacodynamic effects>
Slovenian: <Farmakodinamični učinki>
English: <For instructions on <reconstitution> <dilution> of the medicinal product before administration, see section <6.6> <and> <12>.>
Slovenian: <Za navodila glede <rekonstitucije> <redčenja> zdravila pred dajanjem, glejte poglavje <6.6> <in> <12>.>
English: <Date of latest renewal: {DD month YYYY}>
Slovenian: <Datum zadnjega podaljšanja: <{DD. mesec LLLL}>
English: <[See Annex I - To be completed nationally]> [For referral procedures, as appropriate]
Slovenian: <[glejte Prilogo I - izpolni država članica]> [For referral procedures, as appropriate]
English: 6.6 Special precautions for disposal <and other handling>
Slovenian: 6.6 Posebni varnostni ukrepi za odstranjevanje <in ravnanje z zdravilom>
English: <Use in children <and adolescents>>
Slovenian: <Uporaba pri otrocih <in mladostnikih>>
English: <For the full list of excipients, see section 6.1.>
Slovenian: <Za celoten seznam pomožnih snovi glejte poglavje 6.1.>
English: <The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.>
Slovenian: <Razdelilna zareza je namenjena le delitvi tablete za lažje požiranje in ne delitvi na dva enaka odmerka.>
English: <Absorption>
Slovenian: <Absorpcija>
English: <Additional side effects in children <and adolescents>>
Slovenian: <Dodatni neželeni učinki pri otrocih <in mladostnikih>>
English: <{DD month YYYY}>
Slovenian: <{DD. mesec LLLL}>
English: <Pharmacokinetic/pharmacodynamic relationship(s)>
Slovenian: <Farmakokinetično/farmakodinamično razmerje>
English: <Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 <or {name of the residue(s)}>.>
Slovenian: <Preobčutljivost na zdravilno učinkovino (zdravilne učinkovine) ali katero koli pomožno snov, navedeno v poglavju 6.1 <ali {imena ostankov topil}>.>
English: Do not <take> <use> X<:>
Slovenian: Ne <jemljite> <uporabljajte> zdravila X<:>
English: The active substance(s) is (are)…
Slovenian: Zdravilna(e) učinkovina(e) je(so) …
English: <Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.>
Slovenian: <Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.>
English: <Detailed information on this medicinal product is available on the website of {name of MS Agency (link)}>
Slovenian: <Podrobne informacije o zdravilu so objavljene na spletni strani {Ime agencije v državi članici (povezava)}.>
English: <The score line is not intended for breaking the tablet.>
Slovenian: <Zareza ni namenjena delitvi tablete.>
English: <X contains {name the excipient(s)}>
Slovenian: <Zdravilo X vsebuje {ime pomožne(ih) snovi}>
English: <Distribution>
Slovenian: <Porazdelitev>
English: <Pregnancy>
Slovenian: <Nosečnost>
English: <[To be completed nationally]> [For referral procedures]
Slovenian: <[izpolni država članica]> [For referral procedures]
English: What X contains
Slovenian: Kaj vsebuje zdravilo X
English: <If you <take> <use> more X than you should>
Slovenian: <Če ste <vzeli> <uporabili> večji odmerek zdravila X, kot bi smeli>
English: The other <ingredient(s)> <(excipient(s))> is (are)...
Slovenian: Druge <sestavina(e) zdravila> <(pomožna(e) snov(i))> so...
English: <The European Medicines Agency has waived the obligation to submit the results of studies with <{(Invented) Name}> [or for generics: <the reference medicinal product containing {name of the active substance(s)}>] in all subsets of the paediatric population in {condition as per Paediatric Investigation Plan (PIP) decision, for the granted indication} (see section 4.2 for information on paediatric use).>
Slovenian: <Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom {(izmišljeno) ime}> [ali za generična zdravila: <referenčno zdravilo, ki vsebuje {ime zdravilne(-ih) učinkovine(učinkovin)}>] za vse podskupine pediatrične populacije {pod pogoji, ki so za odobreno indikacijo zdravila navedeni v izvedbenem načrtu za pediatrično populacijo (PIP)} (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).>
English: <The European Medicines Agency has deferred the obligation to submit the results of studies with <{(Invented) Name}> [or for generics: <the reference medicinal product containing {name of the active substance(s)}>] in one or more subsets of the paediatric population in {condition, as per Paediatric Investigation Plan (PIP) decision, for the granted indication} (see section 4.2 for information on paediatric use).>
Slovenian: <Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom {(izmišljeno) ime}> [ali za generična zdravila: <referenčno zdravilo, ki vsebuje {ime zdravilne(-ih) učinkovine(učinkovin)}>] za eno ali več podskupin pediatrične populacije {pod pogoji, ki so za odobreno indikacijo zdravila navedeni v izvedbenem načrtu za pediatrično populacijo (PIP)} (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).>
English: <Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:>
Slovenian: <V kliničnih študijah niso opazili neželenih učinkov, opazili pa so jih v študijah na živalih pri stopnjah izpostavljenosti, ki so bile podobne stopnjam klinične izpostavljenosti.
English: <If you forget to <take> <use> X>
Slovenian: <Če ste pozabili <vzeti> <uporabiti> zdravilo X>
English: <This medicine is subject to additional monitoring.
Slovenian: < Za to zdravilo se izvaja dodatno spremljanje varnosti.
English: <Not relevant.>
Slovenian: <Podatek ni potreben.>
English: {name MS/Agency} will review any new information on this medicine every year and this leaflet will be updated as necessary.>
Slovenian: {Ime države članice/Agencije} bo vsako leto ponovno pregledala vse nove podatke o zdravilu.
English: The {name MS/Agency} will review any new information which may become available every year and this SmPC will be updated as necessary>
Slovenian: {Ime države članice/Agencije} bo vsako leto pregledala vse nove podatke, ki bodo na voljo.
English: <Elimination>
Slovenian: <Izločanje>
English: How to <take> <use> X
Slovenian: Kako <jemati> <uporabljati> zdravilo X
English: <Fertility>
Slovenian: <Plodnost>
English: <- This medicine has been prescribed for you only.
Slovenian: <- Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
English: <{X} should not be used in children aged {x to y} <years> <months> [or any other relevant subsets, e.g. weight, pubertal age, gender] because of <safety> <efficacy> concern(s).>
Slovenian: <Zdravila {X} se ne sme uporabljati pri otrocih, starih {x do y} <let> <mesecev>, [ali drugi primerni skupini, npr. glede na telesno maso, dobo pubertete, spol] zaradi pomislekov glede <varnosti> <učinkovitosti>.>
English: <{X} is contraindicated in children aged {x to y} <years> <months> [or any other relevant subsets, e.g. weight, pubertal age, gender] <for the indication of...> (see section 4.3).>
Slovenian: <Zdravilo {X} je kontraindicirano pri otrocih, starih {x do y} <let> <mesecev>, [ali drugi primerni skupini, npr. glede na telesno maso, dobo pubertete, spol] <za indikacijo...> (glejte poglavje 4.3).>
English: See the end of section 4 for how to report side effects.> [For medicinal products subject to additional monitoring ONLY]
Slovenian: Glejte na koncu poglavja 4, kako poročati o neželenih učinkih.>
English: <If you stop <taking> <using> X>
Slovenian: <Če ste prenehali <jemati> <uporabljati> zdravilo X>
English: <You must talk to a doctor if you do not feel better or if you feel worse <after {number of} days>.>
Slovenian: <Če se znaki vaše bolezni poslabšajo ali ne izboljšajo <v {število} dneh>, se posvetujte z zdravnikom.>
English: <There is no relevant use of {X} <in the paediatric population> <in children aged {x to y} <years>, <months> [or any other relevant subsets, e.g. weight, pubertal age, gender] <for the indication of...>.>
Slovenian: <Zdravilo {X} ni namenjeno za uporabo <pri pediatrični populaciji> <pri otrocih starih {x do y} <let>, <mesecev> [ali drugi primerni skupini npr. glede na telesno maso, dobo pubertete, spol] <za indikacijo...>.>
English: <The <safety> <and> <efficacy> of {X} in children aged {x to y} <months> <years> [or any other relevant subsets, e.g. weight, pubertal age, gender] <has> <have> not <yet> been established.>
Slovenian: <<Varnost> <in> <učinkovitost> zdravila {X} pri otrocih, starih {x do y} <mesecev> <let> [ali drugi primerni skupini, npr. glede na telesno maso, dobo pubertete, spol] <še> <ni><nista> <bila><bili> <dokazana><dokazani>.>
English: You must talk to a doctor if you do not feel better or if you feel worse <after {number of} days.>>
Slovenian: Če se znaki vaše bolezni poslabšajo ali ne izboljšajo <v {število} dneh>, se posvetujte z zdravnikom.>
English: <If you have any further questions on the use of this medicine, ask your <doctor> <,> <or> <pharmacist>< or nurse>.>
Slovenian: <Če imate dodatna vprašanja o uporabi zdravila, se posvetujte <z>
 <zdravnikom><,> <ali> <farmacevtom> <ali medicinsko sestro>.>
English: <Always <take> <use> this medicine exactly as described in this leaflet or as your <doctor> <,> <or> <pharmacist> <or nurse> <has> <have> told you.
Slovenian: <Pri <jemanju> <uporabi> tega zdravila natančno upoštevajte napotke v tem navodilu ali navodila <zdravnika><,> <ali> <farmacevta> <ali medicinske sestre>.
English: If you have any further questions, ask your <doctor> <,> <or> <pharmacist> <or nurse>.
Slovenian: Če imate dodatna vprašanja, se posvetujte <z>
 <zdravnikom><,> <ali> <farmacevtom> <ali medicinsko sestro>.
English: <Always <take> <use> this medicine exactly as your doctor <or pharmacist> has told you.
Slovenian: <Pri <jemanju> <uporabi> tega zdravila natančno upoštevajte navodila zdravnika <ali farmacevta>.
English: PARTICULARS TO APPEAR ON <THE OUTER PACKAGING> <AND> <THE IMMEDIATE PACKAGING>
Slovenian: PODATKI NA <ZUNANJI OVOJNINI> <IN> <PRIMARNI OVOJNINI>
English: Talk to your doctor <or> <,> <pharmacist> <or nurse> before <taking> <using> X
Slovenian: Pred začetkom <jemanja> <uporabe> zdravila X se posvetujte z zdravnikom <ali> <farmacevtom> <ali medicinsko sestro>.
English: If you get any side effects, talk to your <doctor> <or> <,> <pharmacist> <or nurse>.
Slovenian: Če opazite kateri koli neželeni učinek, se posvetujte <z>
 <zdravnikom><,> <ali><farmacevtom> <ali medicinsko sestro>.
English: If you get any side effects, talk to your <doctor> <,> <or> <pharmacist> <or nurse>.
Slovenian: Če opazite kateri koli neželeni učinek, se posvetujte <z>
 <zdravnikom><,> <ali> <farmacevtom> <ali medicinsko sestro>.
English: Nature and contents of container
Slovenian: 6.5 Vrsta ovojnine in vsebina
English: {Route of administration}
Slovenian: {pot uporabe}
English: They may also block the multiplication of viruses.
Slovenian: Zavirajo lahko tudi razmnoževanje virusov.
English: Some studies also looked at signs of improvement of the condition of the liver.
Slovenian: V nekaterih študijah so proučevali tudi znake izboljšanja stanja jeter.
English: The exact way that they work in viral diseases is not fully understood, but it is thought that they act as immunomodulators (substances that modify how the immune system works).
Slovenian: Natančen način njihovega delovanja pri virusnih boleznih ni v celoti znan, vendar se domneva, da delujejo kot imunomodulatorji (snovi, ki spreminjajo način delovanja imunskega sistema).
English: This decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
Slovenian: To zmanjšuje hitrost njegovega izločanja iz telesa in omogoča manj pogosto dajanje zdravila.
English: The full EPAR for ViraferonPeg can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo ViraferonPeg je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for ViraferonPeg on 29 May 2000.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom ViraferonPeg, veljavno po vsej EU, odobrila dne 29. maja 2000.
English: In adults, the most common side effects with ViraferonPeg (seen in more than 1 patient in 10) are viral infection, pharyngitis (sore throat), anaemia (low red blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell), loss of appetite, depression, anxiety, emotional lability (mood swings), impaired concentration, insomnia (difficulty sleeping), headache, dizziness, dyspnoea (difficulty breathing), cough, vomiting, nausea (feeling sick), abdominal pain (stomach ache), diarrhoea, dry mouth, alopecia (hair loss), pruritus (itching), dry skin, rash, myalgia (muscle pain), arthralgia (joint pain), musculoskeletal pain (pain in the muscles and bones), reactions at the site of the injection, inflammation at the site of the injection, fatigue (tiredness), asthenia (weakness), irritability, chills, pyrexia (fever), influenza (flu)-like illness and weight loss.
Slovenian: Pri odraslih bolnikih so bili najpogostejši neželeni učinki zdravila ViraferonPeg (opaženi pri več kot 1 bolniku od 10) virusne okužbe, faringitis (vneto žrelo), anemija (nizke ravni rdečih krvnih celic), nevtropenija (nizke ravni nevtrofilcev, vrste belih krvnih celic), izguba teka, depresija, anksioznost, čustvena labilnost (nihanje razpoloženja), motnje koncentracije, nespečnost (težave s spanjem), glavobol, omotica, dispneja (oteženo dihanje), kašelj, bruhanje, navzeja (občutek slabosti), bolečine v trebuhu, driska, suha usta, alopecija (izpadanje las), pruritus (srbenje), suha koža, izpuščaji, mialgija (bolečine v mišicah), artralgija (bolečine v sklepih), mišično-skeletne bolečine (bolečine v mišicah in kosteh), reakcije na mestu injiciranja, vnetje na mestu injiciranja, utrujenost, astenija (šibkost), razdražljivost, mrzlica, pireksija (povišana telesna temperatura), gripi podobna bolezen in izguba telesne mase.
English: The duration of treatment depends on the patient's condition and response to treatment, and ranges from six months to a year.
Slovenian: Trajanje zdravljenja je odvisno od bolnikovega stanja in odziva na zdravljenje ter traja od šestih mesecev do enega leta.
English: The replacement acts in the same way as naturally produced interferon alpha.
Slovenian: Nadomestek deluje enako kot naravno proizvedeni interferon alfa.
English: Depending on the severity of the side effects treatment may have to be stopped altogether (including boceprevir).
Slovenian: Glede na resnost neželenih učinkov bo morda treba z zdravljenjem (tudi z boceprevirjem) popolnoma prenehati.
English: It must not be used in patients who have had severe heart disease or an auto-immune disease (a disease caused by the body's own defence system attacking normal tissue), or in children or adolescents who have had severe mental disorders, particularly severe depression, thoughts about committing suicide or suicide attempts.
Slovenian: Ne sme se uporabljati pri bolnikih s hudim srčnim obolenjem ali avtoimunsko boleznijo (boleznijo, ki jo povzroča lastni obrambni sistem telesa, ki napada normalno tkivo) ter otrocih in mladostnikih s hudimi duševnimi boleznimi, zlasti hudo depresijo, samomorilnimi mislimi ali poskusi samomora.
English: For more information about treatment with ViraferonPeg, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom ViraferonPeg preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: The CHMP decided that ViraferonPeg's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila ViraferonPeg večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: Because ViraferonPeg is linked to side effects such as depression, patients must be closely monitored during treatment.
Slovenian: Ker je zdravilo ViraferonPeg povezano z neželenimi učinki, kot je depresija, je treba bolnike med zdravljenjem pozorno spremljati.
English: This document is a summary of the European Public Assessment Report (EPAR) for ViraferonPeg.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo ViraferonPeg.
English: In children and adolescents, the dose is 60 micrograms per square metre body surface area (calculated using the patient's height and weight).
Slovenian: Pri otrocih in mladostnikih znaša odmerek 60 mikrogramov na kvadratni meter telesne površine (ki se izračuna na podlagi bolnikove telesne višine in mase).
English: These contain 50, 80, 100, 120 or 150 micrograms of peginterferon alfa-2b in 0.5 ml.
Slovenian: Obe obliki v 0,5 ml vsebujeta 50, 80, 100, 120 ali 150 mikrogramov peginterferona alfa-2b.
English: The main measure of effectiveness in these studies was the number of patients who had no detectable hepatitis C virus in their blood 24 weeks after the end of the treatment and could therefore be considered to be cured.
Slovenian: Glavno merilo učinkovitosti v teh študijah je bilo število bolnikov, pri katerih 24 tednov po koncu zdravljenja v krvi ni bilo mogoče zaznati virusa hepatitisa C in je bilo zato mogoče šteti, da so ozdravljeni.
English: Other information about ViraferonPeg:
Slovenian: Druge informacije o zdravilu ViraferonPeg:
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ViraferonPeg.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo ViraferonPeg, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Peginterferon alfa-2b is similar to interferon alfa-2b, which has been available in the European Union (EU) for a number of years.
Slovenian: Peginterferon alfa-2b je podoben interferonu alfa-2b, ki je v Evropski uniji (EU) na voljo že več let.
English: The first study involved previously untreated patients while the second study involved patients who had failed previous treatment.
Slovenian: Prva študija je vključevala predhodno nezdravljene bolnike, druga pa bolnike, pri katerih predhodno zdravljenje ni bilo uspešno.
English: Dual therapy with ribavirin is also used in previously untreated children and adolescents (aged between three and 17 years) as long as their liver is still working normally.
Slovenian: Dvotirno zdravljenje z ribavirinom se uporablja tudi pri predhodno nezdravljenih otrocih in mladostnikih (starih od 3 do 17 let), v kolikor njihova jetra še vedno delujejo normalno.
English: The main measure of effectiveness was the level of hepatitis C virus circulating in the blood before and after six months or a year of treatment, and at ‘follow-up', six months later.
Slovenian: Glavno merilo učinkovitosti je bila raven hepatitisa C v krvi pred zdravljenjem, po šestih mesecih ali enem letu zdravljenja ter ob kontrolnem pregledu šest mesecev pozneje.
English: The Committee noted that the dual combination with ribavirin was shown to be effective against longterm hepatitis C virus infection in adults and children.
Slovenian: Odbor je opozoril, da se je dvotirno zdravljenje z ribavirinom izkazalo za učinkovito pri dolgotrajni okužbi z virusom hepatitisa C pri odraslih in otrocih.
English: In adults, it is used in combination treatments at a dose of 1.5 micrograms per kilogram body weight, or on its own at 0.5 or 1.0 micrograms/kg.
Slovenian: Če se pri odraslih uporablja v kombinaciji z drugimi zdravili, znaša njegov odmerek 1,5 mikrograma na kilogram telesne mase, pri uporabi kot samostojno zdravilo pa 0,5 ali 1 mikrogram na kilogram telesne mase.
English: What benefit has ViraferonPeg shown during the studies?
Slovenian: Kakšne koristi je zdravilo ViraferonPeg izkazalo med študijami?
English: ViraferonPeg is also linked to weight loss and reduced growth in children and adolescents.
Slovenian: Zdravilo ViraferonPeg je povezano z izgubljanjem telesne mase in zmanjšano telesno rastjo pri otrocih in mladostnikih.
English: ViraferonPeg must not be used in patients with a severe medical condition, severe liver problems, thyroid disease that is not controlled, epilepsy or other central nervous system problems.
Slovenian: Zdravilo ViraferonPeg se ne sme uporabljati pri bolnikih z resnim obolenjem, s hudimi težavami z jetri, z nenadzorovanim obolenjem ščitnice, epilepsijo ali drugimi motnjami delovanja osrednjega živčnega sistema.
English: Treatment with ViraferonPeg should be started and supervised by a doctor who has experience in the management of patients with hepatitis C. ViraferonPeg is given once a week as an injection under the skin.
Slovenian: Zdravljenje z zdravilom ViraferonPeg mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hepatitisom C. Zdravilo ViraferonPeg se daje enkrat tedensko z injekcijo v podkožje.
English: ViraferonPeg must not be used in people who are hypersensitive (allergic) to any interferon or any of the other ingredients.
Slovenian: Zdravila ViraferonPeg ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) katero koli vrsto interferona ali katero drugo sestavino zdravila.
English: For a full list of restrictions, see the package leaflet.
Slovenian: Za celoten seznam omejitev glejte navodilo za uporabo.
English: The combination of ViraferonPeg with ribavirin was effective in patients with cirrhosis and in patients infected with HIV.
Slovenian: Kombinacija zdravila ViraferonPeg in ribavirina je bila učinkovita pri bolnikih s cirozo in bolnikih, okuženih z virusom HIV.
English: It is available as a powder and solvent that are made up into a solution for injection, and as a single-use prefilled pen.
Slovenian: Na voljo je v obliki praška in vehikla za pripravo raztopine za injiciranje ter napolnjenega injekcijskega peresnika za enkratno uporabo.